Clinical Trials Logo

Stage III Breast Cancer AJCC v7 clinical trials

View clinical trials related to Stage III Breast Cancer AJCC v7.

Filter by:

NCT ID: NCT05334069 Recruiting - Melanoma Clinical Trials

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Start date: August 1, 2022
Phase:
Study type: Observational

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

NCT ID: NCT04197687 Recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Start date: February 20, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.

NCT ID: NCT04054557 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

This phase II trial studies how well telehealth works in improving adherence to endocrine (anti-estrogen) therapy in participants with estrogen receptor and/or progesterone receptor positive (hormone receptor positive) stage 0-III breast cancer who have underwent surgery. Telehealth is an approach to care that uses digital information and communication tools to manage health and well-being. Participants interact with their health care providers via a video chat on a computer or smart phone. Telehealth may help identify the effects of treatment on participants with breast cancer who have underwent surgery.

NCT ID: NCT03872388 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Start date: January 14, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atorvastatin works in treating patients with stages IIb-III triple negative breast cancer who did not achieve a pathologic complete response to neoadjuvant chemotherapy. Pathologic complete response is the lack of all signs of cancer in tissue samples removed during surgery after upfront chemotherapy. Atorvastatin is used for the treatment of high cholesterol and may reduce the risk of triple negative breast cancer from coming back. Triple-negative breast cancer is a type of breast malignancy that is comprised of cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. Patients with TNBC do not have established systemic therapies such as anti-estrogens or HER2-targeting agents to reduce recurrence after surgery, and residual cancer found at surgery is associated with higher relapse rate.

NCT ID: NCT03428802 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Start date: March 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03411070 Completed - Clinical trials for Stage IIIC Breast Cancer AJCC v7

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

Start date: April 7, 2019
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery. The SCOUT localization system with the SAVI reflector is non-radioactive and completely internal so can be placed into an abnormal lymph node prior to chemotherapy treatment, which theoretically will allow easier identification and therefore more reliable targeting of the abnormal lymph node for surgical removal.

NCT ID: NCT03407716 Completed - Cancer Survivor Clinical Trials

Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors

Start date: March 1, 2019
Phase: Early Phase 1
Study type: Interventional

This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decrease fatigue in people who were treated for cancer.

NCT ID: NCT03391453 Recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Proton Beam Radiation Therapy in Treating Patients With Breast Cancer After Surgery

Start date: May 10, 2016
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well proton beam radiation therapy works in treating patients with breast cancer after surgery. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors.

NCT ID: NCT03326258 Withdrawn - Metastatic Melanoma Clinical Trials

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Start date: April 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as glembatumumab vedotin, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03317405 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

Start date: October 31, 2018
Phase: Phase 1
Study type: Interventional

This randomized phase I trial studies the side effects and best dose of endoxifen hydrochloride in treating participants who are undergoing breast surgery. Endoxifen hydrochloride may treat or reduce the risk of breast cancer.